UPDATE: SVB Leerink On Mednax Market Perform Initiation: Firm Warns On Deteriorating "Stable" Trends Coupled With Few Signs Of Improvement In End-Markets; Estimates FY21 Organic EBITDA To Decline By 10% With 'Costs Growing 2 Times Faster Than Revenues'